Rallybio Corp Cash Flow Statement
RLYB|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$49M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Rallybio Corp used $49M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$57.8M | -$74.6M |
| Depreciation & Amortization | $131.0K | $150.0K |
| Operating Cash Flow | -$49.3M | -$60.3M |
| Capital Expenditures | - | $12.0K |
| Free Cash Flow | - | -$60.3M |
| FCF Margin | - | -10046.2% |